ClinicalTrials.gg
RecruitingNCT05799092SMART-STEPUpdated Nov 20, 2025

Invasive Versus Non-invasive Approach in Symptomatic Patient With Non-High Risk Coronary Artery Stenosis

An interventional study of Invasive coronary angiography and Non-invasive functional test in Coronary Artery Disease, sponsored by Samsung Medical Center. Recruiting at 22 sites in South Korea. Open to participants aged 19 Years and older. Per ClinicalTrials.gov, last updated 2025-11-20.

Sponsored by Samsung Medical Center · Not applicable, Interventional, and Diagnostic

How we know

From the registry’s dates

  • Started Oct 2023; still recruiting 3 years 1 month later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
2,000
Allocation
Randomized
Ages
19 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 31 studies in Coronary Artery Disease by Samsung Medical Center — 10 open to participants now, 14 under way, none of them phase 3. Coronary Artery Disease · Samsung Medical Center.

Planned enrollment
6th of 21
2,000 · median 520
Started
2023
with 2 others
No phase
16 of 31
5 open now
Primary completion
2029-06
later than 9 of 13 live
Registered
21st of 31
by date

Among the 31 studies in Coronary Artery Disease by Samsung Medical Center, this one is the 6th largest by planned enrollment of the 21 interventional ones that give a count, is one of 3 that started in 2023, is one of 16 with no phase, reaches primary completion later than 9 of the 13 other live ones, and was the 21st registered.

Coronary Artery Disease

4,866 studies on the registry are indexed under Coronary Artery Disease; 892 are open to participants now.

Browse Coronary Artery Disease studies →

Open to participants now

10 of the 31 studies in Coronary Artery Disease by Samsung Medical Center are open now, in 1 country. Recruiting first, the newest first:

4 more — sign in →

By country, each count listing its studies:

All 10 open studies →

Where they have run

Who these studies take

Of the 591 Coronary Artery Disease studies recruiting now, 404 (68%) set no upper age limit and 68 (12%) stop at 75 or younger; 37 take children under 18; 49 take healthy volunteers.

This study: 19 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 31 studies in Coronary Artery Disease by Samsung Medical Center, or all of them as a file.
02

Study summary

A pragmatic, prospective, multi-center, open label, randomized controlled, superiority trial.

The study will compare clinical outcomes between invasive versus non-invasive approach as next diagnostic step in symptomatic patients with non-high risk obstructive coronary artery disease (CAD) on coronary computed tomography-angiography (CCTA).

Read the detailed description

CCTA has been emerged as useful diagnostic tool to evaluate CAD. Besides high diagnostic accuracy, CCTA has additional benefit of measuring the cumulative atherosclerotic burden and more accurately discriminating obstructive CAD with additional fractional flow reserve by CT (FFRCT), making it more predictive of a patient's prognosis. Recently, several randomized clinical trials have demonstrated the clinical utility of CCTA when compared with noninvasive stress test, which has been previously widely used as an initial assessment for stable chest pain, or invasive coronary angiography, which is the gold standard for diagnosing obstructive CAD.

On this background, CCTA, along with stress imaging test, is recommended as first step to diagnose obstructive CAD in patients with intermediate to high pretest probabilities with stable chest pain and is increasingly utilized. Although CCTA is increasingly used as initial assessment tool in these patients, there are insufficient studies to clearly establish the next step after obstructive CAD is confirmed in CCTA. Without high-risk features of CAD on CCTA, current guidelines suggest noninvasive stress imaging or FFRCT as class IIA recommendation. However, supporting evidence of these suggestions are mostly based on studies with low level of evidence. Furthermore, given the limited diagnostic performance of noninvasive stress test, concern remains whether it is safe to defer invasive coronary angiography based on the result from noninvasive stress test in patients with obstructive CAD on CCTA.

Therefore, this trial aims to compare clinical outcomes between invasive versus non-invasive approach as next diagnostic step in symptomatic patients with non-high risk obstructive CAD on CCTA.

03

Conditions studied

  • Coronary Artery Disease

Keywords

  • Coronary Computed Tomography Angiography
  • Non-High Risk Obstructive CAD
  • Diagnostic Approach
  • Invasive Coronary Angiography
  • Non-Invasive Functional Test
04

Who can participate

Ages eligible
19 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Subject age ≥19 years old
  2. Patients with new or worsening chest pain syndrome, equivalent symptoms, or abnormal laboratory test findings (suspected ischemic changes in electrocardiography, regional wall motion abnormality in echocardiography, or coronary calcium score > 100) suspected for CAD who are evaluated by CCTA
  3. Any other clinical circumstance in which physician judged to proceed CCTA
  4. Obstructive CAD in CCTA (≥50% diameter stenosis)
  5. Subject who can verbally confirm understandings of risks, benefits, and treatment alternatives of receiving invasive approach and he/she or his/her legally authorized representative provides written prior to any study related procedure.

Exclusion criteria

Exclusion Criteria:

  1. Diagnosed or suspected acute coronary syndrome (ACS) requiring hospitalization or urgent or emergent testing (elevated cardiac troponin or CK-MB)
  2. High risk CAD (left main stenosis ≥ 50%; anatomically significant 3-vessel disease with ≥70% stenosis)
  3. Hemodynamically or clinically unstable condition (systolic BP \< 90 mmHg, ventricular arrhythmias, or persistent resting chest pain in ischemic nature despite adequate therapy
  4. Known CAD with previous MI, percutaneous coronary intervention (PCI), coronary artery bypass graft (CABG)
  5. Known true anaphylaxis to contrast medium (not allergic reaction but anaphylactic shock)
  6. Known significant congenital, severe valvular or cardiomyopathic (hypertrophic or dilated cardiomyopathy, or any other forms) process which could explain cardiac symptoms.
  7. Severe left ventricular systolic dysfunction ( \<30%)
  8. Intolerance to Aspirin, Clopidogrel, or Heparin.
  9. Non-cardiac co-morbid conditions are present with \<2 year or that may result in protocol non-compliance (per site investigator's medical judgment)
  10. Unwillingness or inability to comply with the procedures described in this protocol.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

05

Study design

Phase
Not applicable
Primary purpose
Diagnostic
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Investigator, Outcomes assessor)
Enrollment
2,000 participants (estimated)

Study arms

  • Experimental
    Invasive approach group

    Invasive coronary angiography will be performed as next diagnostic step in symptomatic patients with non-high risk obstructive CAD on CCTA..

    Diagnostic Test: Invasive coronary angiography

  • Active comparator
    Non-invasive approach group

    Usual care of non-invasive ischemia testing (exercise electrocardiography \[ECG\], stress echocardiography by exercise or pharmacologic agent, nuclear test including SPECT or PET, stress cardiac magnetic resonance \[MR\]) will be performed as next diagnostic step in symptomatic patients with non-high risk obstructive CAD on CCTA.

    Diagnostic Test: Non-invasive functional test

Interventions

  • Diagnostic testInvasive coronary angiography

    As alternative to non-invasive functional testing, invasive coronary angiography will be performed.

  • Diagnostic testNon-invasive functional test

    Standard non-invasive functional testing will be performed.

06

What researchers measure

Primary outcomes

  1. Time to first event of major adverse cardiac events (MACE)

    MACE is a composite of death from any causes, myocardial infarction (MI), clinically driven unplanned revascularization.

    Time frame: 2 years after the last patient enrollment

Secondary outcomes

  1. All-cause death

    All-cause death

    Time frame: 2 years after the last patient enrollment

  2. Cardiac death

    Cardiac death

    Time frame: 2 years after the last patient enrollment

  3. Any MI

    Defined by Forth Universal definition of MI

    Time frame: 2 years after the last patient enrollment

  4. Spontaneous MI

    Defined by Forth Universal definition of MI

    Time frame: 2 years after the last patient enrollment

  5. Procedure-related MI

    Defined by ARC II definition

    Time frame: 2 years after the last patient enrollment

  6. Resuscitated cardiac arrest

    Resuscitated cardiac arrest

    Time frame: 2 years after the last patient enrollment

  7. Unplanned revascularization (clinically driven)

    Unplanned revascularization (clinically driven)

    Time frame: 2 years after the last patient enrollment

  8. Cerebrovascular accidents

    Cerebrovascular accidents (ischemic or hemorrhagic)

    Time frame: 2 years after the last patient enrollment

  9. Major adverse cardiac and cerebrovascular events

    Major adverse cardiac and cerebrovascular events (MACCE, a composite of death, MI, clinically-driven unplanned revascularization, or cerebrovascular accident)

    Time frame: 2 years after the last patient enrollment

  10. Rate of index coronary angiography

    Rate of index coronary angiography

    Time frame: up to 30 days following randomization

  11. Rate of index revascularization by PCI or CABG

    Rate of index revascularization by PCI or CABG

    Time frame: up to 30 days following randomization

  12. European Quality of Life-5 Dimensions

    European Quality of Life-5 Dimensions

    Time frame: 6 months after initial management according to allocated diagnostic test

  13. Seattle Angina Questionnaire

    Seattle Angina Questionnaire

    Time frame: 6 months after initial management according to allocated diagnostic test

  14. Total medical cost

    Total medical cost

    Time frame: 2 years after the last patient enrollment

  15. Procedure-related complications from invasive procedure

    Procedure-related complications from invasive procedure

    Time frame: up to 30 days following randomization

07

Study locations

22 of 22 sites recruiting
08

References and documents

Individual participant data

Plan to share: Yes — After publication of first manuscript and trial results, the de-identified data will be shared by permission of principle investigator, when asked

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: After publication of first manuscript and trial results, the de-identified data will be shared by permission of principle investigator, when asked

Access criteria: After publication of first manuscript and trial results, the de-identified data will be shared by permission of principle investigator, when asked

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2023 (actual). Primary completion is estimated for Jun 2029, 68 months after the start.

Of 756 non-industry interventional studies with no phase under Coronary Artery Disease, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 53. This study's planned 68 months is above that.

Counting every sponsor, half of 933 studies reached it within 30 months; a quarter within 15 and three quarters within 50.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 22, 2023
First posted
Apr 5, 2023
StartActual
Oct 2, 2023
Primary completionEst.
Jun 30, 2029
CompletionEst.
Dec 31, 2030
Last update
Nov 20, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 20, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05799092
Responsible party
Joo Myung Lee (Professor, Samsung Medical Center) — Principal investigator
First posted
Apr 5, 2023
Start date
Oct 2, 2023
Primary completion
Jun 30, 2029 (estimated)
Completion
Dec 31, 2030 (estimated)
Last update
Nov 20, 2025

Study contacts

Joo Myung Lee, MD, MPH, PhD
Contact
drone80@hanmail.net
82-2-3410-3391
David Hong, MD
Contact
hongdawi@naver.com
82-2-3410-3391
Joo Myung Lee, MD, MPH, PhD
principal investigator · Samsung Medical Center

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion